The short version of peptide hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-25 and is reviewed periodically as new material appears.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Cocaine is known to suppress hunger and appetite by increasing co-localization of sigma σ1R receptors and ghrelin GHS-R1a cell surface receptors, thereby increasing ghrelin-mediated signaling of satiety and possibly via other effects on appetitive hormones. Cocaine effects, further, are shown to be potentiated for the user when used in conjunction with new surroundings and stimuli, and otherwise novel environs.
=== Apodization in photography === Most camera lenses contain diaphragms which decrease the amount of light coming into the camera. These are not strictly an example of apodization, since the diaphragm does not produce a smooth transition to zero intensity, nor does it shape the intensity profile beyond the "top hat" transmission of its aperture. Some lenses use other methods to reduce the amount of light let in. For example, the Minolta/Sony STF 135mm f/2.8 T4.5 lens has a special design which accomplishes this by using a concave neutral-gray-tinted lens element as an apodization filter, thereby producing a pleasant bokeh. The same optical effect can be achieved by combining depth-of-field bracketing with multiple exposure, as implemented in the Minolta Maxxum 7's STF function. In 2014, Fujifilm announced a lens utilizing a similar apodization filter in the Fujinon XF 56mm F1.2 R APD lens. In 2017, Sony introduced the E-mount full-frame lens Sony FE 100mm F2.8 STF GM OSS (SEL-100F28GM) based on the same optical Smooth Trans Focus principle. Simulation of a Gaussian laser beam input profile is also an example of apodization. Photon sieves provide a relatively easy way to achieve tailored optical apodization.
Polydimethylsiloxane (PDMS) Poly(caprolactone (PCL) Poly(lactide) (PLA) Poly(methyl methacrylate) (PMMA) If enough of the block copolymer molecules that make up a polymersome are cross-linked, the polymersome can be made into a transportable powder. Polymersomes can be used to make an artificial cell if hemoglobin and other components are added. The first artificial cell was made by Thomas Chang.
Action and Adventure (Sponsored by PC World) – Crackdown Artistic Achievement – Ōkami Best Game – BioShock Casual – Wii Sports Gameplay (Sponsored by Nokia N-Gage) – Wii Sports Innovation – Wii Sports Multiplayer – Wii Sports Original Score – Ōkami Sports – Wii Sports Story and Character – God of War II Strategy and Simulation – Wii Sports Technical Achievement – God of War II Use of Audio – Crackdown BAFTA One's To Watch Award (in association with Dare to Be Digital) – Ragnarawk The PC World Gamers Award (voted for by the public) – Football Manager 2007 Academy Fellowship – Will Wright
Sources: en.wikipedia.org
The introduction of Di(2-propylheptyl) phthalate (DPHP) was driven by increasing regulatory scrutiny and health concerns associated with traditional plasticizers. DPHP was developed to meet the demand for plasticizers with improved safety profiles, particularly in applications involving human contact. As a result of its production through the esterification of phthalic anhydride with 2-propylheptanol, it results in a compound with low volatility and high thermal stability, making it suitable for various applications, including automotive interiors, wire and cable insulation, and flooring materials. The compound gained regulatory attention in the European Union, where it was included in the Community Rolling Action Plan (CoRAP) under the REACH regulation in 2014. This inclusion was due to concerns about its widespread use, potential endocrine-disrupting properties, and exposure risks to sensitive populations. Germany was tasked with evaluating DPHP's health and environmental impacts, with the assessment process beginning in 2020. Research into DPHP's metabolism and exposure markers has been conducted to better understand its behavior in biological systems. A 2019 study utilized ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) in a rat model to identify potential biomarkers for DPHP exposure, aiding in the assessment of human exposure levels.
Most class III adenylyl cyclases are transmembrane proteins with 12 transmembrane segments. The protein is organized with 6 transmembrane segments, then the C1 cytoplasmic domain, then another 6 membrane segments, and then a second cytoplasmic domain called C2. The important parts for function are the N-terminus and the C1 and C2 regions. The C1a and C2a subdomains are homologous and form an intramolecular 'dimer' that forms the active site. In Mycobacterium tuberculosis and many other bacterial cases, the AC-III polypeptide is only half as long, comprising one 6-transmembrane domain followed by a cytoplasmic domain, but two of these form a functional homodimer that resembles the mammalian architecture with two active sites. In non-animal class III ACs, the catalytic cytoplasmic domain is seen associated with other (not necessarily transmembrane) domains. Class III adenylyl cyclase domains can be further divided into four subfamilies, termed class IIIa through IIId. Animal membrane-bound ACs belong to class IIIa.
==== Oceania ==== In 1967, the first 99mTc procedures were carried out in Auckland, New Zealand. 99Mo was initially supplied by Amersham, UK, then by the Australian Nuclear Science and Technology Organisation (ANSTO) in Lucas Heights, Australia.
=== Dosage units === One international unit of insulin (1 IU) is defined as the "biological equivalent" of 34.7 μg pure crystalline insulin. The first definition of a unit of insulin was the amount required to induce hypoglycemia in a rabbit. This was set by James Collip at the University of Toronto in 1922. Of course, this was dependent on the size and diet of the rabbits. The unit of insulin was set by the insulin committee at the University of Toronto. The unit evolved eventually to the old USP insulin unit, where one unit (U) of insulin was set equal to the amount of insulin required to reduce the concentration of blood glucose in a fasting rabbit to 45 m g/d L (2.5 m mol/L). Once the chemical structure and mass of insulin was known, the unit of insulin was defined by the mass of pure crystalline insulin required to obtain the USP unit. The unit of measurement used in insulin therapy is not part of the International System of Units (abbreviated SI) which is the modern form of the metric system. Instead the pharmacological international unit (IU) is defined by the WHO Expert Committee on Biological Standardization.
==== Russian preparations and invasion of Georgia ==== The commission noted, "the sum of actions undertaken by Russia by mid-2008 amounted to a threat of force vis-à-vis Georgia", and that Georgia felt "a substantial risk of Russian military intervention". The commission noted that "Russian military operations in Georgia in August 2008 appear to most analysts to have been well-planned and well-executed." The commission noted that many international experts "also believe that the massive Russian military action in August 2008 caught the Georgians off guard and unprepared both strategically and tactically." The commission noted that Russian military base Ugardanta in the Dzau District and Russian military rehabilitation centre in the north-west Tskhinvali were constructed before the August 2008 conflict. As far as legality of use of force by Russia was concerned, the report took a "differentiated" approach, dividing "the Russian reaction to the Georgian attack" into two phases – the one, which was "the immediate reaction in order to defend Russian peacekeepers" in Tskhinvali and the second one, "the invasion of Georgia by Russian armed forces reaching far beyond the administrative boundary of South Ossetia", which was "beyond the reasonable limits of defence".
Sources: en.wikipedia.org
====== Graduate programs in drug development ====== The MS program with drug development specialization (MSDD) is a two-year, online degree program in global pharmaceutical development (drugs/biologicals, drug products and devices). Tailored to meet the aspirations of working professionals, the program can be completed on a part-time basis with coursework offered on-site in the evening on weekdays or via distance learning. A collaboration between academia, industry, and government, MSDD provides cross-disciplinary training in the scientific, regulatory and business aspects of drug development.
Further, chemical biology employs biological systems to create non-natural hybrids between biomolecules and synthetic devices (for example, emptied viral capsids that can deliver gene therapy or drug molecules).
=== Other uses === A 2003 meta-analysis of existing research showed naloxone to improve blood flow in patients with shock, including septic, cardiogenic, hemorrhagic, or spinal shock, but could not determine if this reduced patient deaths. Oral naloxone has been used for opioid-induced constipation (OIC). A 2018 meta-analysis cites 5 studies that tests it for this purpose. It found that medical treatment for OIC can be more efficacious than placebo, but did not look into the effect of individual treatments such as naloxone. As a result, no conclusion can be drawn from the study on naloxone's effectiveness for OIC. Naloxone and other opioid antagonists have been examined as possible treatments for dissociative disorders. This use predicates on the theory that dissociative disorders cause disregulation in the body's natural opioid pathways. A 2023 meta-analytic study found some evidence of opioid antagonists being effective against dissociative disorders, but possible publication bias and differences in testing criteria encourages additional research.
A third Reform UK councillor on Cornwall Council resigns making the Liberal Democrats the single largest party. 25 October – Lucy Powell wins the 2025 Labour Party deputy leadership election. 26 October – Former Bank of England governor Mervyn King criticises a potential mansion tax. 27 October – A report from the Home Affairs Select Committee claims that the Home Office has "squandered" billions of pounds of taxpayers' money on asylum accommodation. Two Reform UK councillors on Kent County Council are expelled from the party for "bringing it into disrepute". 28 October – Steve Reed, Secretary of State for Housing, Communities and Local Government, announces that Surrey County Council will be abolished and replaced by two unitary authorities; East Surrey and West Surrey. Stormont appoints Pól Deeds and Lee Reynolds as Northern Ireland's first Irish language and Ulster-Scots commissioners respectively. 29 October – Chancellor Rachel Reeves refers herself to the Parliamentary Commissioner for Standards after saying that she broke housing rules by unlawfully renting out her family home without a licence. The Electoral Management Board for Scotland announces that votes for the 2026 Scottish Parliament election will be counted the day after the election rather than overnight. 30 October – Plaid Cymru leader Rhun ap Iorwerth and SNP leader John Swinney hold talks to develop a "progressive alliance" between the two parties. 31 October – Prince Andrew is formally stripped of his prince title and will henceforth be known as Andrew Mountbatten-Windsor.
=== Health === In 1996, Morgan was diagnosed with diabetes mellitus and for years has been an alcoholic. Morgan has conceded that many of his own troubles were incorporated within 30 Rock episodes. In early December 2010, Morgan received a kidney transplant necessitated by his diabetes and alcohol use. In August 2023, Morgan responded to a comment about his healthy appearance during an episode of Today with Hoda & Jenna by disclosing that he was using semaglutide. In March 2024, he told Jimmy Fallon that he had "learned to out-eat Ozempic" and "gained 40 lbs," but later clarified that he was joking, saying "Ozempic did great by me and I was glad to use it." On March 17, 2025, while sitting courtside at an NBA basketball game at Madison Square Garden between the New York Knicks and Miami Heat, Morgan experienced an episode of food poisoning, which caused him to vomit onto the basketball court sideline and suffer a bloody nose. He joked on his Instagram post from the hospital saying, "More importantly, the Knicks are now 1-0 when I throw up on the court so maybe I'll have to break it out again in the playoffs."
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.